{
    "ticker": "TCON",
    "name": "TRACON Pharmaceuticals, Inc.",
    "description": "TRACON Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative cancer therapies. Founded in 2010 and based in San Diego, California, TRACON is dedicated to advancing targeted therapies that improve the lives of cancer patients. The company's lead product candidate, TRC105, is an anti-angiogenesis therapy designed to inhibit blood vessel growth in tumors. TRACON is also developing a pipeline of product candidates that target various cancer types and mechanisms, including immuno-oncology approaches. The company's commitment to precision medicine is reflected in its focus on identifying biomarkers that predict patient response to treatment, which aims to optimize patient outcomes. With a strong team of industry veterans, TRACON seeks to address the unmet needs of patients and healthcare providers in the oncology space, leveraging its expertise in drug development and clinical trials. TRACON's mission is to accelerate the delivery of new therapies to patients facing difficult-to-treat cancers.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2010",
    "website": "https://www.traconpharma.com",
    "ceo": "Charles Theuer",
    "social_media": {
        "twitter": "https://twitter.com/traconpharma",
        "linkedin": "https://www.linkedin.com/company/tracon-pharmaceuticals"
    },
    "investor_relations": "https://ir.traconpharma.com",
    "key_executives": [
        {
            "name": "Charles Theuer",
            "position": "CEO"
        },
        {
            "name": "W. Scott W. H. Leung",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapies",
            "products": [
                "TRC105",
                "TRC253"
            ]
        }
    ],
    "seo": {
        "meta_title": "TRACON Pharmaceuticals, Inc. | Innovative Cancer Therapies",
        "meta_description": "Explore TRACON Pharmaceuticals, Inc., a leader in developing innovative cancer therapies aimed at improving patient outcomes through targeted treatments.",
        "keywords": [
            "TRACON",
            "Cancer Therapy",
            "Biopharmaceuticals",
            "Oncology",
            "Targeted Therapy",
            "TRC105"
        ]
    },
    "faq": [
        {
            "question": "What does TRACON Pharmaceuticals focus on?",
            "answer": "TRACON Pharmaceuticals focuses on developing innovative cancer therapies."
        },
        {
            "question": "Who is the CEO of TRACON Pharmaceuticals?",
            "answer": "Charles Theuer is the CEO of TRACON Pharmaceuticals, Inc."
        },
        {
            "question": "Where is TRACON Pharmaceuticals headquartered?",
            "answer": "TRACON Pharmaceuticals is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are TRACON's main product candidates?",
            "answer": "TRACON's main product candidates include TRC105 and TRC253."
        },
        {
            "question": "When was TRACON Pharmaceuticals founded?",
            "answer": "TRACON Pharmaceuticals was founded in 2010."
        }
    ],
    "competitors": [
        "CLVS",
        "AZN",
        "BMY",
        "EXEL"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "MRNA"
    ]
}